clinical trial · NCT04113551
A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan
Janssen Research & Development, LLC·—·completed·n = 17,418
Attention Deficit Disorder With HyperactivityMPH (Concerta)MPH (Ritalin)Atomoxetine (ATO)Guanfacine (GFC)
brief summary
The purpose of this study is to document the extent of on-label and off-label use of Methylphenidate (MPH) (Concerta), MPH (Ritalin), Atomoxetine (ATO), and Guanfacine (GFC) in Japan.
started
Oct 1, 2019
primary completion
Jan 10, 2020
completion
Jan 10, 2020
last updated
Apr 27, 2025
official title
Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan: A Retrospective Cohort Study of Label Compliance
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol